Based on the Pacira BioSciences, Inc. stock forecast from 6 analysts, the average analyst target price for Pacira BioSciences, Inc. is USD 33.89 over the next 12 months. Pacira BioSciences, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Pacira BioSciences, Inc. is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Pacira BioSciences, Inc.’s stock price was USD 22.91. Pacira BioSciences, Inc.’s stock price has changed by -7.81% over the past week, -1.97% over the past month and -19.56% over the last year.
No recent analyst target price found for Pacira BioSciences, Inc.
No recent average analyst rating found for Pacira BioSciences, Inc.
Company Overview Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Read Less
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable susp...Read More
Frequently Asked Questions About Pacira BioSciences, Inc. (PCRX) Stock
Based on ratings from 6 analysts Pacira BioSciences, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 6 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on PCRX's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for PCRX is USD 33.89 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 17.
PCRX stock's Price/Earning ratio is 12.37.
Our analysis grades PCRX stock's Price / Earning ratio at D-. This means that PCRX stock's Price/Earning ratio is above 38% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this PCRX may be fairly valued for its sector
The last closing price of PCRX's stock was USD 22.91.
The most recent market capitalization for PCRX is USD 1.07B.
Based on targets from 6 analysts, the average taret price for PCRX is projected at USD 33.89 over the next 12 months.
This means that PCRX's stock price may go up by +47.92% over the next 12 months.
We can't find any ETFs which contains Pacira BioSciences, Inc.'s stock.
As per our most recent records Pacira BioSciences, Inc. has 788 Employees.
Pacira BioSciences, Inc.'s registered address is 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609.
You can get more information about it from Pacira BioSciences, Inc.'s website at https://www.pacira.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Pacira BioSciences, Inc. (PCRX) Stock
Based on ratings from 6 analysts Pacira BioSciences, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 6 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on PCRX's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for PCRX is USD 33.89 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 17.
PCRX stock's Price/Earning ratio is 12.37.
Our analysis grades PCRX stock's Price / Earning ratio at D-. This means that PCRX stock's Price/Earning ratio is above 38% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this PCRX may be fairly valued for its sector
The last closing price of PCRX's stock was USD 22.91.
The most recent market capitalization for PCRX is USD 1.07B.
Based on targets from 6 analysts, the average taret price for PCRX is projected at USD 33.89 over the next 12 months.
This means that PCRX's stock price may go up by +47.92% over the next 12 months.
We can't find any ETFs which contains Pacira BioSciences, Inc.'s stock.
As per our most recent records Pacira BioSciences, Inc. has 788 Employees.
Pacira BioSciences, Inc.'s registered address is 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609.
You can get more information about it from Pacira BioSciences, Inc.'s website at https://www.pacira.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PCRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
